Missing satellite cost NZ extra $3m because of delays
Photo:
Supplied / Environmental Defence Fund
A satellite that has
gone missing in space
cost taxpayers $32 million, $3m more than originally planned, because of delays.
The extra cost was to staff a mission control that will now never be used to drive the satellite.
Leading scientists say too few questions were asked before deciding to invest in the mission, and red flags were missed.
However New Zealand Space Agency and scientists who worked on the mission say New Zealand has gained valuable experience.
The Space Agency, which sits inside the Ministry of Business, Innovation & Employment (MBIE), says multiple delays to the satellite's launch meant University of Auckland needed more money to keep employing staff at its mission control centre.
The agency says $26m of the total was spent on New Zealand-based organisations.
Delays to the launch pushed out the date when the university was meant to take over the mission control.
The handover was then delayed another six months when the satellite was handed back to its manufacturer to work on unspecified problems.
The handover was finally due to happen in late June, when the satellite was lost.
The final cost to the government included $6m to the MethaneSAT organisation for flight software and other items, $12m to Rocket Lab for scoping and establishing the mission control, which it ran for the first year after launch, $6m to the University of Auckland to operate the mission control centre after Rocket Lab handed it over, and $6m to Earth Sciences NZ (formerly NIWA) for a science programme to measure farming's emissions methane from space.
The final $2m was for MBIE to manage the programme.
Earth Sciences NZ says the agricultural science programme already has a wealth of data and will continue as planned. The lead scientist for MethaneSAT says there's very little chance the satellite will be recovered.
The mission is a collaboration with the US-based Environmental Defense Fund.
Its chief scientist and MethaneSAT mission lead Dr Steven Hamburg said they did not know what caused the satellite to lose power and become unresponsive on 20 June.
"There's a very small chance, we were able to observe it by using another satellite to look at it and it does not currently have power. We are working it, we continue to work it, but we have to be realistic the probability of recovery is diminishing."
Hamburg said a group was investigating the cause.
RNZ has been asking about problems with the satellite since September and
was previously told its issues were "teething problems"
.
Hamburg said the MethaneSAT had been transparent, and the Space Agency said the mission had kept people as informed "as possible."
However University of Auckland physics professor Richard Easther said the space craft carrying the methane detector "seems to have had fairly persistent and deep-seated problems, pretty much from launch."
He said for most of the year it had been in orbit, it was not functioning properly.
Associate Professor Nicholas Rattenbury of the Department of Physics at University of Auckland said he sympathised with those involved in the mission, but the question needed to be asked of whether New Zealand should have taken a closer look "under the hood" before investing in MethaneSAT.
Dr Rattenbury questioned who was asking questions on behalf of taxpayers about the mission design, satellite construction and testing before the government committed the money.
He said the science sector had "very limited resources" to spend.
Space Minister Judith Collins has
declined to comment
on the loss or whether the public had been adequately informed during the mission.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
RNZ News
3 hours ago
- RNZ News
Study finds "no safe amount" of processed meat
A new study has found there is "no safe amount" of processed meat to eat. University of Auckland associate professor Dr Kathryn Bradbury spoke to Tuwhenuaroa Natanahira. Tags: To embed this content on your own webpage, cut and paste the following: See terms of use.
Scoop
6 hours ago
- Scoop
Project Aims To Bring Cutting-Edge Cancer Treatments To NZ
Press Release – University of Auckland Cell-based therapies are the most advanced and promising treatments for cancer,' says Didsbury, who is an immunologist, committee chair at the International Society for Cell and Gene Therapy, and a trustee for Ovarian Cancer Foundation NZ. Plans are under way to bring life-saving cell-based cancer treatments to patients in New Zealand. Dr Alicia Didsbury from the University of Auckland's Centre for Cancer Research is leading a major project aiming to provide cell and gene therapies for cancer. The project is supported by the New Zealand Blood Service and doctors at Auckland City Hospital. Didsbury is applying for $1.4 million for the first phase of the project, which will offer virus-specific T-cell therapy for people with blood cancers who are undergoing treatments that lower their immunity. Virus-specific T-cells fight viruses more effectively and with fewer side effects than antiviral medications, which are currently used widely. The aim is for the first phase to begin later this year, establishing the country's first facility to manufacture virus-specific T-cells and a local biobank of T-cells. From there, the plan is to launch New Zealand's first clinical trials of cell-based treatments for a broad range of blood cancers and solid tumour cancers over the next few years. 'Cell-based therapies are the most advanced and promising treatments for cancer,' says Didsbury, who is an immunologist, committee chair at the International Society for Cell and Gene Therapy, and a trustee for Ovarian Cancer Foundation NZ. 'At the moment, access to cellular therapies is extremely limited in New Zealand, so some patients go overseas and have to pay hundreds of thousands of dollars for these life-saving treatments.' Blood-cancer patients who receive stem-cell transplants are generally given immune suppressant medication to prevent complications. This can leave patients vulnerable to potentially life-threatening viral infections. New Zealand currently imports a small number of virus-specific T-cells, but these are expensive and not always a good match for Māori and Pacific populations, says Didsbury. 'By manufacturing virus-specific T-cells here in Auckland, we can create more affordable and better-matched therapies using local donor cells,' says Didsbury. 'For some people undergoing transplants, this could be lifesaving.' Launching a virus-specific T-cell manufacturing and treatment service in Auckland will help build the basis to launch national and international clinical trials for cell-based treatments for blood and solid tumour cancers. The second phase of the project will make experimental treatments for multiple myeloma, melanoma, ovarian and lung cancers available in New Zealand for the first time. 'I'm a strong advocate for clinical trials in cancer care. They offer hope to patients and contribute to research that brings hope to others in the future,' says Didsbury. Initially, the project will launch at Auckland Hospital, but Didsbury hopes clinical trials will later be offered throughout New Zealand. For blood cancers, cell-based therapies show remarkable results. For solid tumours, cellular treatments are more experimental and have only completely cured a small percentage of patients in overseas trials. CAR T-cell therapy is one of the most promising treatments that will be offered. It harnesses the natural ability of T-cells – white blood cells that normally detect and kill virus-infected cells – to target cancer. In this therapy, a patient's own T cells are collected and genetically modified in the lab to recognise and kill cancer cells. These modified cells are then infused back into the patient to fight the cancer. CAR T-cell therapy can currently cost more than $500,000 per patient, so the project will explore affordable ways to offer these treatments within the public health system. The new service also aims to offer other cell and gene-based cancer therapies, such as transgenic T-cell receptor therapy and tumour-infiltrating lymphocyte therapy. Didsbury's drive to make cancer treatments more accessible and affordable has personal roots. 'My dad passed away from cancer when I was 21 and that motivated me to pursue a career in cancer research – initially thinking I'd go into drug discovery. 'Then, in 2005, I attended a lecture from a scientist who had recently returned from Oxford who introduced me to the new idea of T-cell therapy – that was Professor Rod Dunbar. It completely changed my direction. I decided to do a PhD with him and he's still my boss at the University of Auckland's School of Biological Sciences,' she says. The 46-year-old has been developing cell-based treatments for cancer for 15 years. A breakthrough treatment she helped develop for melanoma could soon be offered in clinical trials.
Scoop
7 hours ago
- Scoop
Project Aims To Bring Cutting-Edge Cancer Treatments To NZ
Plans are under way to bring life-saving cell-based cancer treatments to patients in New Zealand. Dr Alicia Didsbury from the University of Auckland's Centre for Cancer Research is leading a major project aiming to provide cell and gene therapies for cancer. The project is supported by the New Zealand Blood Service and doctors at Auckland City Hospital. Didsbury is applying for $1.4 million for the first phase of the project, which will offer virus-specific T-cell therapy for people with blood cancers who are undergoing treatments that lower their immunity. Virus-specific T-cells fight viruses more effectively and with fewer side effects than antiviral medications, which are currently used widely. The aim is for the first phase to begin later this year, establishing the country's first facility to manufacture virus-specific T-cells and a local biobank of T-cells. From there, the plan is to launch New Zealand's first clinical trials of cell-based treatments for a broad range of blood cancers and solid tumour cancers over the next few years. 'Cell-based therapies are the most advanced and promising treatments for cancer," says Didsbury, who is an immunologist, committee chair at the International Society for Cell and Gene Therapy, and a trustee for Ovarian Cancer Foundation NZ. 'At the moment, access to cellular therapies is extremely limited in New Zealand, so some patients go overseas and have to pay hundreds of thousands of dollars for these life-saving treatments.' Blood-cancer patients who receive stem-cell transplants are generally given immune suppressant medication to prevent complications. This can leave patients vulnerable to potentially life-threatening viral infections. New Zealand currently imports a small number of virus-specific T-cells, but these are expensive and not always a good match for Māori and Pacific populations, says Didsbury. 'By manufacturing virus-specific T-cells here in Auckland, we can create more affordable and better-matched therapies using local donor cells,' says Didsbury. 'For some people undergoing transplants, this could be lifesaving." Launching a virus-specific T-cell manufacturing and treatment service in Auckland will help build the basis to launch national and international clinical trials for cell-based treatments for blood and solid tumour cancers. The second phase of the project will make experimental treatments for multiple myeloma, melanoma, ovarian and lung cancers available in New Zealand for the first time. 'I'm a strong advocate for clinical trials in cancer care. They offer hope to patients and contribute to research that brings hope to others in the future,' says Didsbury. Initially, the project will launch at Auckland Hospital, but Didsbury hopes clinical trials will later be offered throughout New Zealand. For blood cancers, cell-based therapies show remarkable results. For solid tumours, cellular treatments are more experimental and have only completely cured a small percentage of patients in overseas trials. CAR T-cell therapy is one of the most promising treatments that will be offered. It harnesses the natural ability of T-cells – white blood cells that normally detect and kill virus-infected cells – to target cancer. In this therapy, a patient's own T cells are collected and genetically modified in the lab to recognise and kill cancer cells. These modified cells are then infused back into the patient to fight the cancer. CAR T-cell therapy can currently cost more than $500,000 per patient, so the project will explore affordable ways to offer these treatments within the public health system. The new service also aims to offer other cell and gene-based cancer therapies, such as transgenic T-cell receptor therapy and tumour-infiltrating lymphocyte therapy. Didsbury's drive to make cancer treatments more accessible and affordable has personal roots. 'My dad passed away from cancer when I was 21 and that motivated me to pursue a career in cancer research – initially thinking I'd go into drug discovery. 'Then, in 2005, I attended a lecture from a scientist who had recently returned from Oxford who introduced me to the new idea of T-cell therapy – that was Professor Rod Dunbar. It completely changed my direction. I decided to do a PhD with him and he's still my boss at the University of Auckland's School of Biological Sciences,' she says. The 46-year-old has been developing cell-based treatments for cancer for 15 years. A breakthrough treatment she helped develop for melanoma could soon be offered in clinical trials.
